Study suggests new treatments for jaw tumors
Nature Genetics
May 26, 2014
Two genes linked to ameloblastomas, tumors of the jaw, are reported in a paper published online this week in Nature Genetics. The results suggest promising treatment options for these destructive jaw tumors.
Ameloblastomas are rare, benign tumors that often lead to facial disfigurement. Robert West and colleagues identified two genes, SMO and BRAF, that are often mutated in ameloblastomas. In their samples, tumors of the upper jaw tended to have SMO mutations, whereas the lower jaw tumors tended to have BRAF mutations. For each gene, the researchers identified an FDA-approved drug that can inhibit the mutant form in human cells. More testing is needed to see if these drugs can help ameloblastoma patients.
doi: 10.1038/ng.2986
Research highlights
-
Jan 13
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
-
Dec 23
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications
-
Dec 21
Epidemiology: Underdetection of COVID-19 after the first lockdown in FranceNature
-
Dec 18
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
-
Dec 17
Epidemiology: Mapping gaps in measles vaccination coverageNature
-
Dec 17
Neuroscience: When you’re smiling, the whole world smiles with youNature
